Pfizer: FDA approves drug for rare neurological disorder
(CercleFinance.com) - The US Food and Drug Administration has approved a Pfizer drug that treats patients with a rare neurological disease called chronic inflammatory demyelinating polyneuropathy.
Panzyga is an intravenous immunoglobulin that achieves viral reduction through a combination of three steps, the US drugmaker said in a statement on Monday.
In a Phase 3 study including 142 patients, 80% of patients achieved a decrease in their disability score, Pfizer said.
Chronic inflammatory demyelinating polyneuropathy is a rare disorder of the peripheral nerves, marked by gradually sensory loss and weakness associated with loss of deep tendon reflexes.
Its characteristics can delay diagnosis by several months or even years, resulting in significant nerve damage that may limit and delay the response to therapy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Panzyga is an intravenous immunoglobulin that achieves viral reduction through a combination of three steps, the US drugmaker said in a statement on Monday.
In a Phase 3 study including 142 patients, 80% of patients achieved a decrease in their disability score, Pfizer said.
Chronic inflammatory demyelinating polyneuropathy is a rare disorder of the peripheral nerves, marked by gradually sensory loss and weakness associated with loss of deep tendon reflexes.
Its characteristics can delay diagnosis by several months or even years, resulting in significant nerve damage that may limit and delay the response to therapy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.